He, Yuwei
Xue, Xiaomei
Terkeltaub, Robert
Dalbeth, Nicola
Merriman, Tony R.
Mount, David B.
Feng, Zhe
Li, Xinde
Cui, Lingling
Liu, Zhen
Xu, Yan
Chen, Ying
Li, Hailong
Ji, Aichang
Ji, Xiaopeng
Wang, Xuefeng
Lu, Jie
Li, Changgui http://orcid.org/0000-0002-4622-3731
Funding for this research was provided by:
national natural science foundation of china (#81770869, #81900636, #31900413)
national key research and development program (#2016YFC0903401)
shandong province key research and development program (#2018CXGC1207)
shandong province natural science foundation (#ZR2018ZC1053)
national institutes of health (#AR060772, #AR075990)
Article History
Received: 15 July 2021
Accepted: 13 January 2022
First Online: 25 January 2022
Declarations
:
: The study was approved by the ethics committee of the Affiliated Hospital of Qingdao University.Informed consent was obtained from all patients.
: Not applicable.
: Robert Terkeltaub is funded by a research award from Astra-Zeneca and has consulted with Horizon, Selecta, SOBI, and Astra-Zeneca. Nicola Dalbeth reports grants and personal fees from AstraZeneca, grants from Amgen, personal fees from Dyve Biosciences, personal fees from JW Pharmaceuticals, personal fees from Selecta, personal fees from Arthrosi, personal fees from Horizon, personal fees from Abbvie, personal fees from Janssen, personal fees from PK Med, outside the submitted work. David Mount reports personal fees from Horizon, Allena Pharmaceuticals, and Alnylam. The other authors declare that they have no competing interests.